Follow the latest coverage, related explainers and connected technology stories.
The U.S. Food and Drug Administration granted Abbott de novo authorization for the Libre Duo 10 Day wearable sensor, which can continuously monitor glucose and ketones in people with diabetes. The company plans to launch it in the United States during 2026, while its price and insurance coverage remain undisclosed.
Abbott is preparing to launch Libre Duo, a sensor that combines glucose and ketone measurement, after receiving the CE mark and submitting an application to the FDA. The device raises practical questions about eligible populations, interpreting readings, educating users, cost, and the limits of relying on ketones alone.